By Ben Glickman
Ventyx released results from its trial of VTX002 in the treatment of ulcerative colitis. The company found that its treatment had a placebo-adjusted clinical remission rate of 17%, at the low end of prior guidance of 15% to 25% and similar to competitor treatments. Shares fall 19% to $24.22 after-hours.
Lexicon Pharmaceuticals secured preferred formulary status for Inpefa, its heart failure treatment, with Express Scripts for Medicare patients beginning on Nov. 1. The drug was approved by the Food and Drug Administration in May. Shares rise 15% to $1.15 after-hours.
Immunic received positive interim data from a Phase 2 trial evaluating a treatment for progressive multiple sclerosis. The interim data showed its treatment led to lower levels of a key biomarker for MS, compared to higher levels in patients receiving the placebo. Shares rose 49% to $2.37 after-hours.
Write to Ben Glickman at [email protected]
Read the full article here
